Translating tumor biology-driven subtypes into actionable genomic signatures for drug response.
GeneCentric’s Cancer Subtyping Platform (CSP®) builds on the pioneering laboratory work of co-founders, Charles Perou, PhD., and Neil Hayes, MD, MPH, MS, innovators in the molecular characterization and treatment of cancer.
By applying CSP technology, GeneCentric is developing universal drug response biomarkers to enable more effective and efficient drug development informed by high resolution, genomic-defined cancer subtypes. This approach is distinct from other strategies which seek to generate biomarkers by profiling responders to specific drugs. Instead, CSP-derived genomic profiles are designed to characterize tumor biology by combining gene expression data with disease-related molecular pathways and immune cell expression through advanced computational biology technologies.
CSP leverages enormous, publicly available gene expression datasets complemented by proprietary data and tools to develop discrete sets of key genes that define cancer subtypes. By reducing the multitude genes associated with each cancer to discrete key gene sets, GeneCentric enables rapid development of tumor specific clinical assays. CSP assays are ‘platform agnostic’, capable of being deployed on established, commercial instruments.
GeneCentric’s ability to identify and reduce to practice a select set of genes that define cancer subtypes and predict drug response underlies the company’s core patents and proprietary position. Our intellectual property includes technology licensed from the University of North Carolina, based on technology developed by Drs. Perou and Hayes, as well as technology developed by GeneCentric.